Heterogeneity of asthma with nasal polyposis phenotypes: A cluster analysis.

BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) affects a significant number of asthmatic patients and is notably associated with a more difficult-to-control asthma and marked inflammation. We need more studies on this specific asthma phenotype and its possible subphenotypes, in order to better individualize treatments. AIM: The aim of this study is to identify and characterize subphenotypes of asthma patients with CRSwNP using clinical, physiological and inflammatory variables. METHODS: K-means cluster analysis was performed on 17 clinical, physiological, and inflammatory variables from 1263 patients of all asthma severity and on a subpopulation of patients with asthma and CRSwNP. Study was registered on ClinicalTrials.gov (NCT03694847). RESULTS: On the overall population, three groups were identified. Cluster T1 (n = 708) are young, have a short asthma duration and a low prevalence of CRSwNP. Cluster T2 (n = 263) have the longest asthma duration and Cluster T3 (n = 292) are older with the shortest asthma duration. Patients in Clusters T2 and T3 have similar prevalences of CRSwNP. On the subpopulation of asthma with CRSwNP, three clusters were also identified. Cluster S1 (n = 83) have mild-to-moderate asthma with normal lung function. Clusters S2 (N = 53) and S3 (N = 42) include patients with severe asthma and decreased lung function, but those in Cluster S2 have a longer asthma duration, whereas those Cluster S3 have late-onset asthma. CONCLUSIONS: Despite coexistence of asthma and CRSwNP, not all patients have the same evolution of their asthma. Different phenotypes of asthma with CRSwNP can be identified and exploration of the characteristics of these subgroups could lead to a better individualized, targeted management.

Suboptimal treatment response to anti-IL-5 monoclonal antibodies in severe eosinophilic asthmatics with airway autoimmune phenomena.

BACKGROUND: In clinical trials, the two anti-interleukin (IL)-5 monoclonal antibodies (mAbs: mepolizumab and reslizumab) approved to treat severe eosinophilic asthma reduce exacerbations by ∼50-60%. OBJECTIVE: To observe response to anti-IL-5 mAbs in a real-life clinical setting, and to evaluate predictors of suboptimal response. METHODS: In four Canadian academic centres, predefined clinical end-points in 250 carefully characterised moderate-to-severe asthmatic patients were collected prospectively to assess response to the two anti-IL-5 mAbs. Suboptimal response was determined based on failure to reduce maintenance corticosteroid (MCS) or asthma symptoms scores (Asthma Control Questionnaire (ACQ)) or exacerbations, in addition to persistence of sputum/blood eosinophils. Worsening in suboptimal responders was assessed based on reduced lung function by 25% or increase in MCS/ACQ. A representative subset of 39 patients was evaluated for inflammatory mediators, autoantibodies and complement activation in sputum (by ELISA) and for immune-complex deposition by immunostaining formalin-fixed paraffin-embedded sputum plugs. RESULTS: Suboptimal responses were observed in 42.8% (107 out of 250) patients treated with either mepolizumab or reslizumab. Daily prednisone requirement, sinus disease and late-onset asthma diagnoses were the strongest predictors of suboptimal response. Asthma worsened in 13.6% (34 out of 250) of these patients. The majority (79%) of them were prednisone-dependent. Presence of sputum anti-eosinophil peroxidase immunoglobulin (Ig)G was a predictor of suboptimal response to an anti-IL-5 mAb. An increase in sputum C3c (marker of complement activation) and deposition of C1q-bound/IL-5-bound IgG were observed in the sputa of those patients who worsened on therapy, suggesting an underlying autoimmune-mediated pathology. CONCLUSION: A significant number of patients who meet currently approved indications for anti-IL5 mAbs show suboptimal response to them in real-life clinical practice, particularly if they are on high doses of prednisone. Monitoring blood eosinophil count is not helpful to identify these patients. The concern of worsening of symptoms associated with immune-complex mediated complement activation in a small proportion of these patients highlights the relevance of recognising airway autoimmune phenomena and this requires further evaluation.

Optimization of the conditions for preservation of induced sputum: influence of freezing on cellular analysis.

BACKGROUND: Induced sputum (IS) analysis is a noninvasive, valid, and reproducible method for evaluating airway inflammation. It has been suggested that freezing of IS samples in order to delay analysis is feasible. However, the optimal conditions for preservation of IS samples have not been determined. OBJECTIVES: To determine optimal freezing conditions of IS samples, ensuring adequate specimen quality for assessment of cell viability, total cell count, and differential cell count. SUBJECTS AND METHODS: Twenty-one subjects were enrolled: 6 healthy control subjects, 5 patients with allergic rhinitis, 5 patients with mild asthma, and 5 patients with severe asthma. Each came to the laboratory once for IS sampling. Cell plugs were homogenized with dithiothreitol and separated into 12 aliquots. Viability and total and differential cell counts were determined for each aliquot. Bovine serum albumin (BSA) with dimethylsulfoxide (DMSO) was added to half of the aliquots, and fetal bovine serum (FBS) with DMSO was added to the other half. One half of the aliquots containing BSA or FBS were frozen at -20 degrees C, and the other half were frozen at - 80 degrees C. After 3, 7, or 10 days, samples were thawed and total cell counts, viability, and differential cell counts were assessed. RESULTS: Slide quality and total cell counts did not vary significantly according to freezing duration, temperature, or medium when compared to nonfrozen control samples. With FBS at -80 degrees C, cell viability did not vary significantly between control samples and freezing for 3, 7, and 10 days (59% vs 54%, 59% vs 54%, and 58% vs 54%, respectively; p > 0.05), whereas every other condition showed a significant decrease. Freezing did not affect the eosinophil percentage significantly. CONCLUSION: Freezing of IS samples in FBS with DMSO at - 80 degrees C allows adequate preservation of IS specimens. Samples can be kept for at least 10 days in those conditions without significantly altering total cell counts, viability, and eosinophil percentage.